Literature DB >> 7772509

Phenotypic analysis of functional T-lymphocyte subtypes and natural killer cells in human cord blood: relevance to umbilical cord blood transplantation.

P Han1, G Hodge, C Story, X Xu.   

Abstract

Cord blood has been used successfully for stem cell transplantation in several haematological conditions: Fanconi's anaemia, leukaemia and Wiskott-Aldrich syndrome. On account of the low incidence of GVHD observed following cord blood transplantation, it has been suggested that cord blood be used for HLA-matched, or perhaps one or two antigens mismatched, and unrelated stem cell transplantation. Based on an extensive immunophenotype-functional correlation, we determined that cord blood contains mainly immature unprimed T lymphocytes that are predominantly suppressor cells. Recent findings suggest that dysregulated production of cytokines (IL-1, IL-2, TNF alpha) plays a role in GVHD. We showed that T cells in cord blood express receptors for IL-2, TNF alpha, but no receptors for IL-1. Similarly, NK cells, one of the effector cells of GVHD, express receptors for TNF alpha and gamma IFN but do not express receptors for IL-1, nor IL-2R alpha-chain (CD25) although IL-2R beta-chain is expressed. The potential for activation of T lymphocytes and NK cells therefore exists in the context of bone marrow transplantation. However, the high number of suppressor cells in cord blood most likely modulate the activation of lymphocytes and NK cells thereby minimizing GVHD.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7772509     DOI: 10.1111/j.1365-2141.1995.tb08409.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  20 in total

Review 1.  Defective antigen-presenting cell function in human neonates.

Authors:  Paula A Velilla; Maria T Rugeles; Claire A Chougnet
Journal:  Clin Immunol       Date:  2006-09-28       Impact factor: 3.969

2.  Umbilical cord blood T cells express multiple natural cytotoxicity receptors after IL-15 stimulation, but only NKp30 is functional.

Authors:  Qin Tang; Bartosz Grzywacz; Hongbo Wang; Nandini Kataria; Qing Cao; John E Wagner; Bruce R Blazar; Jeffrey S Miller; Michael R Verneris
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

3.  Surface activation markers of T lymphocytes: role in the detection of infection in neonates.

Authors:  S Hodge; G Hodge; R Flower; P Han
Journal:  Clin Exp Immunol       Date:  1998-07       Impact factor: 4.330

Review 4.  Stem cell therapy for type 1 diabetes mellitus.

Authors:  Cristina Aguayo-Mazzucato; Susan Bonner-Weir
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

Review 5.  From cord to caudate: characterizing umbilical cord blood stem cells and their paracrine interactions with the injured brain.

Authors:  Priya F Maillacheruvu; Lauren M Engel; Isaiah T Crum; Devendra K Agrawal; Eric S Peeples
Journal:  Pediatr Res       Date:  2017-11-01       Impact factor: 3.756

6.  T-lymphocyte recovery and function after cord blood transplantation.

Authors:  Paul Szabolcs
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

7.  Phenotypic and functional analysis of human T lymphocytes in early second- and third-trimester fetuses.

Authors:  Y Zhao; Z-P Dai; P Lv; X-M Gao
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

Review 8.  Autologous umbilical cord blood infusion for type 1 diabetes.

Authors:  Michael J Haller; Hilla-Lee Viener; Clive Wasserfall; Todd Brusko; Mark A Atkinson; Desmond A Schatz
Journal:  Exp Hematol       Date:  2008-03-20       Impact factor: 3.084

Review 9.  Immune reconstitution after unrelated cord blood transplantation.

Authors:  P Szabolcs; D Niedzwiecki
Journal:  Cytotherapy       Date:  2007       Impact factor: 5.414

10.  Autologous umbilical cord blood transfusion in very young children with type 1 diabetes.

Authors:  Michael J Haller; Clive H Wasserfall; Kieran M McGrail; Miriam Cintron; Todd M Brusko; John R Wingard; Susan S Kelly; Jonathan J Shuster; Mark A Atkinson; Desmond A Schatz
Journal:  Diabetes Care       Date:  2009-11       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.